Kornimate/medical-research-clean huggingface dataset:
comparison of duloxetine versus pregabalin

Conditions: Drug Effect

Summary: chronic post mastectomy pain syndrome (pmps) is a chronic post-surgical neuropathic pain following breast cancer surgeries and lasting more than three months after surgeries. pregabalin is originally used as an antiepileptic drug and identiﬁed as treatment for neuropathic pain .there are several recent reviews have revealed that it reduces post-operative opioid consumption and improves pain scores after breast surgeries. duloxetine is a serotonin and norepinephrine reuptake inhibitor. its mechanism of action is related to the potentiation of serotonergic and noradrenergic activity in the descending inhibitory pain pathways of the central nervous system and used for treatment of neuropathic pain conditions as painful diabetic neuropathy, neuropathic pain of lung cancer and chemotherapy induced sensory neuropathy

patients with of 3 months of chronic neuropathic pain after breast surgery (either modified radical mastectomy or conservative breast surgery) combined with axillary dissection is considered as post mastectomy pain syndrome which is defined as pain involving the anterior aspect of the chest, axilla, and/or upper arm with the classical features of neuropathic pain including numbness, tingling, burning, shooting, stinging, or stabbing pains, and hyperesthesia. * they are divided to 2 equal groups: ( group a) receive duloxetine for 12 weeks and (group b) control group receive pregabalin for 12 weeks . * dosing and administration group a) duloxetine 30 mg /day at bed time and (group b) control group pregablin 150mg /day( 75 mg /12 hours ) * randomization and blinding: randomization is done using computer generated sequence. concealment will be achieved by opaque envelope. * concomitant therapy :opioid therapy according to who step ladder in cancer pain

Eligibility criteria:
inclusion criteria: * female, history of breast surgery and patients with post mastectomy pain exclusion criteria: * pregnancy,history of allergy to pregabalin or duloxetine, pregnancy or lactation, history of pregabalin or gabapentin intake in the preceding three months, history of radiotherapy and history of drug abuse

Keywords: pregabalin and duloxetine
effect of high school alcohol policies on students' binge drinking- a natural experiment

Conditions: Alcohol Policy; Binge Drinking

Summary: the aim of the project is to evaluate the effects of the introduction of new mutual alcohol policies in 30 high schools in 2017 on students binge drinking.

in august 2017, 13 high schools in zealand and all of funen's 11 high schools and 6 high schools in ringkøbing introduced new mutual alcohol policy for alcohol on study trips, parties, cafes and other social events. the background for the introduction of the alcohol policies was the aim of reducing alcohol intake among students and that alcohol should have a less dominant role. by setting the same framework, the alcohol policies aims at promoting community, responsibility and respect. the aim of the project is to evaluate the effects of the introduction of new mutual alcohol policies on students binge drinking. the analysis is a natural experiment that compare binge drinking among students at schools after the introduction of the policy with binge drinking among students a schools that did not introduce the policy.

Eligibility criteria:
inclusion criteria: * high school student exclusion criteria: -
radar clinical trial

Conditions: Persistent Atrial Fibrillation

Summary: this prospective, multicenter, observational study will examine the ability of real time electrogram processing mapping to identify driver domains to target for ablation in persistent af patients.

abstract: recent clinical trials have shown that targeting rotors and focal impulses (fis) during atrial fibrillation (af) ablation improves outcomes. this study evaluated whether a novel computational mapping algorithm (cma) could identify fis and rotors, and characterize rotors when incidental ablation resulted in rhythm changes. three-dimensional (3d) left atrial electroanatomic maps were created from signals recorded from multipolar circular mapping catheters in 61 patients undergoing persistent af ablation. forty of 61acquired patient datasets were of adequate quality for analysis cma, employing an af pattern recognition algorithm, creating 3d panoramic af maps identifying drivers of af (fi and rotors) post procedure. rotors were further classified as substrate (sbr) or non-substrate based (nsbr) on the basis of rotor stability, proximity to voltage transition zones and complex fractionated atrial electrograms (cfaes). incidentally ablated identified af drivers, including sbrs and nsbrs, were evaluated for rhythm changes. a total of 172 drivers were identified in 40 patients (2.2 drivers/patient). seventy percent were rotors (120/172) and 30% were fis (52/172). sixty-seven percent of rotors were classified as sbr vs 33% as nsbr. incidental ablation of sbrs resulted in rhythm change 91% of the time versus only 24% of the time for nsbr (p\<0.0001).

Eligibility criteria:
inclusion criteria: * ≥ 18 years of age. * patients are considered eligible if they have symptomatic or drug-refractory af and are planned to undergo a catheter ablation procedure for persistent af (ether a first procedure or a redo procedure) * ability to understand the requirements of the study and sign the informed consent form. * willingness to adhere to study restrictions and comply with all post-procedural follow-up requirements * projected lifespan greater than 1 year. exclusion criteria: * they have long-standing persistent af prior to the first procedure (defined as af greater than one year's duration). * rheumatic heart disease * current intra-cardiac thrombus * history of mi or coronary artery bypass grafting (cabg) within 6 weeks * unstable angina * cva or tia within 3 months * contraindication to anticoagulation * class iv hf * unable to sign consent * projected lifespan of \< 1 year * women known to be pregnant or to have positive beta-hcg (human chorionic gonadotropin). * participation in another study that would interfere with this study.

Keywords: persistent atrial fibrillation mapping
botswana vitamin d supplementation study in hiv/aids

Conditions: HIV

Summary: the goal is to determine the vit d supplementation dose that safely results in optimal serum vitamin d (25d) concentrations in hiv-infected children and adults living in botswana. to do this the investigators will test two oral daily doses (4000 vs. 7000 iu) of cholecalciferol (d3) dietary supplement over a 12-week period in 60 children and adults with hiv/aids living in botswana (5.0 to 50.9 yrs), to assess safety as determined by serum calcium and 25d concentrations and efficacy to replete vit d status as determined by achieving a minimum serum 25d concentration of 32 ng/ml (80 nmol/l).

many people living with hiv/aids in african countries are vit d deficient or insufficient. vit d deficiency in hiv/aids may be due to low dietary vit d intake, increased requirements, malabsorption, specific drug therapies (antiretrovirals, in particular), reduced outdoor physical activity, reduced vit d synthesis from uv light exposure in dark skin pigmented individuals, or unknown hiv-associated factors. vit d deficiency likely contributes to abnormal immune status and increased inflammatory state, and to poor growth, bone, and muscle function, and may contribute to risk for tuberculosis (tb) infection. the goal is to determine the vit d supplementation dose that safely results in optimal serum 25d concentrations in hiv-infected children and adults living in botswana. to do this the investigators will test two oral daily doses (4000 vs. 7000 iu) of cholecalciferol (d3) dietary supplement over a 12-week period in 60 children and adults with hiv/aids living in botswana (5.0 to 50.9 yrs), to assess safety as determined by serum calcium and 25d concentrations and efficacy to replete vit d status as determined by achieving a minimum serum 25d concentration of 32 ng/ml (80 nmol/l).

Eligibility criteria:
inclusion criteria: * hiv infection * ages 5.0 to 50.9 y * in usual state of good health * subject and/or family commitment to the 12-week study exclusion criteria: * other chronic health conditions unrelated to hiv/aids that may affect nutritional status * use of vit d supplementation above 400 iu/d

Keywords: vitamin d
cohort construction and prognostic model construction for multiple myeloma

Conditions: Multiple Myeloma

Summary: multiple myeloma (mm) is a disease caused by malignant plasma cell proliferation disorder. survival outcomes continue to vary widely even within uniformly treated clinical trial populations. how to construct a clinical prognosis model of mm through real-world data to guide the selection of treatment options, standardize patient management, and improve survival expectations, is a major problem that needs to be solved urgently. it is necessary to build an mm-specific cohort in china to comprehensively understand the characteristics of mm patients, explore treatment options, and improve prognostic factors for survival outcomes.


Eligibility criteria:
inclusion criteria: patients were diagnosed as multiple myeloma from january 1, 2008 (the diagnostic criteria are based on "chinese guidelines for the diagnosis and treatment of multiple myeloma (revised in 2020)"). exclusion criteria: long-term follow-up information for patients is not available for any reason, such as not being available or having a serious concomitant disease.
effect of moringa oleifera leaves on glycemic control of women with type 2 diabetes

Conditions: Type 2 Diabetes

Summary: the objective of this clinical trial was to understand whether supplementation of moringa oleifera leaf powder improved glycemic management in sahrawi women with type 2 diabetes living in refugee camps. the main question sought to be answered was: - does daily supplementation of moringa oleifera leaf powder, in addition to oral hypoglycemic therapy, improve glycosylated hemoglobin and fasting blood glucose? researchers compared moringa supplementation with no moringa consumption to see if moringa oleifera worked to improve glycemic control. participants had to: * take moringa oleifera leaves daily or abstain from consuming moringa for 3 months. * consistently take prescribed oral hypoglycemic agents * undergo clinical examinations and measurement of biochemical, metabolic and body composition parameters at the time of recruitment and at the end of the study.


Eligibility criteria:
inclusion criteria: * diagnosis of type 2 diabetes for at least 1 year * absence of advanced retinopathy, terminal renal failure, active diabetic ulcers, amputations, and heart failure * treatment with only oral hypoglycemic drugs. exclusion criteria: * diagnosis of type 1 diabetes * pregnancy or lactation * treatment with insulin.

Keywords: moringa oleifera type 2 diabetes humans glucose hba1c
targeting high risk populations with enhanced reactive focal mass drug administration in thailand

Conditions: Plasmodium Falciparum Malaria; Plasmodium Vivax Malaria

Summary: this study assesses the effectiveness of reactive focal mass drug administration (rfmda), targeting both village and forest working populations, compared to control for reducing the health promotion hospital-level (sub-district) incidence and prevalence of p. falciparum and p. vivax within five provinces in thailand.

thailand currently has a well-developed and robust surveillance system based on detailed mapping of all cases to the village foci level and stratification of response. in fiscal year 2019, 5,833 cases of malaria were reported with 83.0% p. vivax and 12.9% p. falciparum; nine deaths were reported. this represents a 20.8% decrease in total cases from fiscal year 2018. currently, there are 701 "a1" villages in 44 provinces. the research proposed here will evaluate the effectiveness and feasibility of enhanced reactive focal mass drug administration, results of which will have direct implications for continued roll out the community-led foci management, providing practical guidance that other malaria programs can utilize. responding to the malaria among high risk populations is a requirement from the national malaria elimination strategy in thailand. additionally, thailand has experienced outbreaks related to forest work over the past several years, and consequently the department of vector borne disease (dvbd) is interested in introducing more aggressive parasite elimination strategies, including rfmda for p. falciparum and p. vivax specifically targeting high-risk populations to interrupt transmission and rapidly accelerate elimination.

Eligibility criteria:
inclusion criteria for rfmda: * index cases: presented as a confirmed malaria case to an intervention health facility or village malaria worker, and lives in a village within a selected intervention subdistrict, or worked or spent at least one night at a forest or forest-fringe site in the past 30 days located within an intervention subdistrict * village residents: lives in a village within a selected intervention subdistrict area and in one of the five households closest to the residence of an index case of malaria * co-worker/traveler referral: worked or traveled and spent at least one night in forest in past 30 days in same location within an intervention subdistrict as an index case of malaria * all participants: willing and available to participate in the study and informed consent for participant under the age of 18 will be provided by the parent or guardian. participants for focus group discussions (fgds) and key informant interviews (kiis); 18 years of age or older exclusion criteria: • for rfmda: * previous participation in the study as a result of any rfmda event in the past 30 days * individuals with severe disease or drug contra-indications will be excluded from the treatment component only * artesunate-mefloquine: pregnancy in the first trimester, or known drug allergy * use of mefloquine within 60 days of first treatment prior to enrollment date.
the effect of pilates exercıses on engine performance and body composition ın primary school children

Conditions: Exercise; Body Weight Changes

Summary: in thıs study, planned for prımary chıldren between 7-11 years, pılates exercıses wıll be done wıth the chıldren who accept to partıcıpate ın the study wıth the accountance of the researcher and compared wıth the control group. evaluatıon; parameters; engıne performance tests and body composıtıon analysıs.

it is a fact that there are disadvantages as well as advantages brought by the development of technology. with this development, individuals adopt a more sedentary lifestyle and daily physical activity and mobility are gradually decreasing. these deficiencies have affected the child population as much as adults. this lack of physical activity in childhood negatively affects the child's growth, development, mood and school success, and increases the risk of chronic diseases in adulthood by preparing the ground for obesity. the positive effects of physical activity on human health are multifaceted. physical, mental, social and cognitive well-being is among its well-known benefits. especially the physical activity and exercise habits gained in childhood contribute greatly to the mental, physical and emotional development of children. the positive effects of the pilates method on individuals' muscular strength and endurance, motor performance and body composition have been reported in many studies. pilates exercise method is a suitable and reliable type of physical activity that can be done for children, and it has positive contributions to the growth, development and postural development of children . our aim in this study, which we will do with 7-11 age group primary school children, is to investigate the effects of regular physical activity and exercise, such as pilates, on both motor ability and body composition. our hypotheses in our study; h1: pilates exercises improve motor ability in primary school children. h2: pilates exercises positively affect body composition in primary school children h3: pilates exercises do not affect motor ability in primary school children. h4: pilates exercises do not affect body composition in primary school children. pilates studies with healthy children are not common in our country. therefore, our study is the first long-term planned (12 weeks 36 sessions) pilates study to be carried out with healthy children at primary school age. apart from this, when looking at the evaluation parameters, criteria such as pain, physical fitness, balance were frequently investigated with pilates. apart from these, motor ability tests and body composition analysis with a bioimpedance body analyzer will be evaluated in our study, and in this sense, it is one of the first pilates studies conducted with healthy children with these parameters.

Eligibility criteria:
inclusion criteria: * agreeing to participate in the study, * no chronic disease, * no sports history exclusion criteria: * failing to complete sessions * presence of chronic disease * engaging in sports activities

Keywords: exercise performance pilates exercise body composi̇ti̇on children
n-3 polyunsaturated fatty acids in the prevention and treatment for ifn-induced depression

Conditions: Major Depressive Episode

Summary: the first part is a double-blind placebo-controlled trial to identify the effects of omega-3 polyunsaturated fatty acids (pufas) in prevention of ifn-induced depression. the second part is a double-blind trial to identify the antidepressant effects of omega-3 pufas in patients with ifn-induced depression.

we have done a preliminary analysis in 63 hcv patients receiving ifn-α therapy enrolled in our current nsc project (nsc95-2320-b-039-037-my3) and found that patients who later developed ifn-α-induced depression (case group, 21/63) had lower pufa levels before starting ifn-α therapy than control group (p=0.024). in addition, there was a trend for a negative correlation (r=-0.224; p=0.078) between baseline dha levels and the highest scores of bdi during ifn therapy in the whole group. these findings indicate that n-3 pufas might play a protective factor. this 3-year proposal is divided into 2 clinical studies. in study 1, we aim to test the prophylactic effect of n-3 pufas (epa: 3.5 g/d and dha: 1.75 g/d versus placebo: high oleic oil) for ifn-α-induced sickness behaviour and depressive symptoms, in a two-week, double-blind, placebo-controlled trial of 152 patients with hcv starting ifn-α therapy. in study 2, we will test the antidepressant effect of n-3 pufas (epa: 3.5 g/d and dha: 1.75 g/d versus placebo: high oleic oil) on ifn-α-induced depression during ifn-α therapy, in an eight-week, double-blind, placebo-controlled trial in 80 hcv patients who have already developed depression.

Eligibility criteria:
inclusion criteria: * eligible participants will be adult patients with chronic hcv, assessed by hepatologists and then referred for ifn-α therapy and have capacity and willingness to give written informed consent exclusion criteria: * patients will be excluded if they have major depressive episode at assessment * any history of pre-existing psychotic disorders (e.g. schizophrenia or bipolar disorder) * alcohol or drug dependence within one year before entry into the study * seizure disorders and evidence of any unstable substantial coexisting medical conditions (e.g. cardiovascular, endocrine, haematological, renal, or neurological diseases)
diabetes risk evaluation and microalbuminuria in saskatchewan first nations peoples

Conditions: Hypertension; Diabetes Mellitus

Summary: this randomized controlled trial was designed to assess whether a community-based treatment strategy implemented by home care nurses would be effective in controlling hypertension in first nations people with existing hypertension and type 2 diabetes.

two community-based strategies for controlling hypertension in first nations people with existing hypertension and diabetes were compared. in the intervention group, a home care nurse followed a predefined treatment algorithm of pharmacologic antihypertensive therapy. in the control group, treatment decisions were made by each subject's primary care physician. the primary outcome measure was the difference between the 2 groups in teh change in systolic blood pressure after 12 months.

Eligibility criteria:
inclusion criteria: * age\>= 18 yr * type 2 diabetes mellitus * persistent hypertension (systolic pressure \>= 130 mmhg, diastolic pressure \>= 80 mm hg, or both) exclusion criteria: * use of beta blocker * women of child-bearing age not able to use a reliable method of birth control * connective tissue disorder * severe systemic or malignant disease * inability to follow the protocol * bilateral renal artery stenosis and other causes of secondary hypertension * serum creatinine level \> 250 micromol/l * cerebrovascular even within 6 mo * valvular heart disease * unstable angina * myocardial infarction * revascularization procedure within 3 mo before study recruitment * heart failure * cardiac arrhythmia requiring medical treatment or heart block * active hepatic disease

Keywords: hypertension type 2 diabetes first nations populations
accuracy of dexcom g6® and freestyle libre® sensors in standardized hypoxemia conditions

Conditions: Type 1 Diabetes Mellitus; Type 2 Diabetes Mellitus

Summary: the major aim is to evaluate accuracy of 2 continuous glucose monitoring systems (cgms) : dexcom g6® and freestyle libre® in standardized hypoxemia conditions (artificial normobaric hypoxia). our purpose is to demonstrate the good performance and calibration of these cgm sensors in hypoxemia conditions.


Eligibility criteria:
inclusion criteria: all population * no history of respiratory diseases (childhood asthma, respiratory allergies, exercise-induced asthma or dyspnea) * willing to participate and able to sign an informed consent form (icf) * being affiliated with the french social security inclusion criteria:patients with diabetes * type 1 diabetes mellitus or type 2 diabetes mellitus (ada definition) * age : 18 to 75 years * stable diabetes treatment for more than 3 months * no diabetic retinopathy * no diabetic neuropathy * no cardiovascular diseases * no contra-indication for coronary computed tomography angiography or myocardial perfusion scintigraphy. inclusion criteria: healthy volunteers * age : 18 ; 40 years * no diabetes * no persistant drug use \> 3 months except contraception * body mass index : \[18,5 - 29,9\] kg/m2 non-inclusion criteria : all population * active smokers * pregnant or breastfeeding women, women of childbearing age without effective contraception * known allergies to the patch. * skin lesions at the sensor site that may interfere with sensor placement or accuracy * major cardiovascular complications within the past 3 months * decompensated congestive heart failure * chronic respiratory failure * chronic renal failure * resting ambient air o2 saturation ≤95%. * treatment with systemic corticosteroids * severe hypertension (≥180 mmhg systolic pressure or ≥ 100 mmhg diastolic pressure) * any concomitant disease or condition that the investigator believes may compromise patient safety or affect the conduct of the study * anemia (hb\<12g/dl) * history of severe mountain sickness * concurrent participation in another clinical research study, * persons benefiting from enhanced protection non-inclusion criteria: patients with diabetes * absolute contraindications to physical activity (has definitin) : * pulmonary arterial hypertension (\> 60 mm hg) * presence of intra-cardiac thrombus * acute pericardial effusion * severe obstructive cardiomyopathy * symptomatic aortic stenosis * recent thrombophlebitis with or without pulmonary embolism

Keywords: cgm (continuous glucose monitoring)